118x188mm

FLUFEN

For Veterinary Use Only

INJECTION

COMPOSITION:
Each ml contains
Florfenicol……..……......300mg
Flunixin as Meglumine……..……16.5mg

INDICATIONS:
It is indicated for the treatment of bovine respiratory disease complex (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni and BRD associated pyrexia.FLUFEN injection is a simple bovine respiratory disease (BRD) treatment strategy. It involves a combination of two therapies in one dose: the powerful antibiotic florfenicol to kill or inhibit the disease-causing bacteria Mycoplasma bovis; and, the fast-acting non-steroidal anti-inflammatory drug (NSAID) Flunixin meglumine to reduce BRD-associated fever in beef and non-lactating dairy cattle.

Characteristics and action Spectrum:
Flunixin Meglumine is a non-steroid anti-inflammatory drug (NSAID) used for analgetic, antiphlogistic and antipyretic purposes in a variety of mammalian species. The mechanism of action of NSAIDs is inhibition of cyclooxygenase (COX), responsible for the synthesis of prostaglandins (PGs) from arachidonic acid.
Florfenicol inhibits microbial protein synthesis by binding to the 50S subunit of the 70S ribosome and impairing peptidyl transferase activity. Because peptide-bond formation is inhibited, peptides cannot elongate. They are bacteriostatic. respiratory tract infections in calves and young pigs by parenteral administration (Hoar et al., 1998; Varma et al.,1998; Jim et al.,1999; Aslan et al., 2002; De Haas et al., 2002; Catry et al., 2008). In calves, the spectrum of activity includes the pneumonia pathogens, Mannheimia haemolytica, Pasteurella multocida and Histophilus somnus (Varma et al.,1998; De Haaset al., 2002; Catry et al., 2008). The latter authors reported no resistance to these species using Kirby-Bauer discs; of the isolates tested, all were sensitive to Florfenicol, with the exception of two of 39 P. multocida isolates, which were intermediate in sensitivity. Similarly, Priebe and Schwarz (2003) reported high activity of florfenicol against these bovine respiratory tract pathogens. Reports of minimum inhibitory concentration (MIC) for P. multocida and M. haemolytica (MIC≤2.0 lg/mL) indicate the relatively high potency of Florfenicol for these organisms (Priebe & Schwarz, 2003; Kehrenberg et al., 2004; Shin et al., 2005; Dowling, 2006; Thiry et al., 2011). However, Ayling et al. (2000) reported high MIC 50 and MIC 90 values of 4 and 16 lg/mL, respect.
Florfenicol was administered intravenously and intramuscularly at a dose rate of 20 mg/kg bodyweight to determine its concentration in blood and bronchial secretions as well as kinetic behavior in healthy and diseased calves. Sever acute bronchopneumonia was induced via inoculating the animals with Pasteurella multocida. The drug is extensively distributed to bronchial secretions.
Florfenicol was slowly eliminated from serum and bronchial secretions with elimination half-lives of (12.43 and 17.23 h) and (13.74 and 22.46 h), respectively, following intramuscular injection.
The clinical and hematological parameters in calves treated intramuscularly returned to normal faster than those treated intravenously.
Flunixin meglumine was administered in all experiments at a nominal dose of 2.2 mg/kg body weight. For I.V. administration, solution for injection, (50 mg/mL) was given into the V. jugularis externa, and for I.M. administration the same formulation was given into the dorsal muscles of the neck.

DOSAGE & ADMINISTRATION:
Flufen injection should be administrated as single subcutaneous injection of Flufen at 2ml/15kg bodyweight, providing 40mg/kg florfenicol and 2.2 mg/kg flunixin. The injection should only be given in the neck.
The dose volume given at any one injection site should not exceed 10ml.

ADVERSE EFFECTS:
Lack of efficacy (rare)
Death
Diarrhea
Ataxia
injection site edema
injection site abscess
lethargy
anorexia
dyspnea
lameness (all very rare)

CONTRAINDICATIONS:
Do not use in animals showing hypersensitivity to flunixin meglumine or florfenicol.
Do not use in adult bulls intended for breeding purposes.
Do not use in animals suffering from hepatic and renal diseases.
Do not use if there is a risk of gastrointestinal bleeding.
And do not use in cases where there is evidence of altered homeostasis.
Do not use in animals known to be hypersensitive to one of the ingredients of the medicine.
Do not use in animals suffering from cardiac diseases.

WITHDRAWAL TIME:
Meat: 46 days.
Milk: Not authorized for use in lactating animals producing milk for human consumption. Do not use during lactation or drying off periods. Do not use in pregnant animals which are intended to produce milk for human consumption within 2 months of expected parturition.

PRECAUTIONS:
Shake well before use.
Consult the veterinarian before use.
Store between 15-25°C in a cool and dry place.
Keep out of the reach of children.

Innovator's Specs.

Selmore Pharmaceuticals (Pvt) Ltd.

Manufactured by:
Selmore Pharmaceuticals (Pvt) Ltd.
36-Km Multan Road, Lahore Pakistan.

ISO CERTIFIED COMPANY